Evidence map›Paper›PMID 41107392›Full record

ArticleScientific reports2025

The paradoxical prognostic effects of T-cell-derived circulating DNA in EGFR-mutated advanced non-small-cell lung cancer involve the crosstalk between heme biosynthesis and immune microenvironment.

Nicha Zungsontiporn, Chaiyapong Ngamchokwathana, Sakun Santisukwongchote, Piyada Sitthideatphaiboon, Nophol Leelayuwatanakul, Krittiya Korphaisarn, Poonchavist Chantranuwat, Virote Sriuranpong, Chatchawit Aporntewan, Nattiya Hirankarn and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicha ZungsontipornDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, ChulalongkornUniversity and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Chaiyapong NgamchokwathanaDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, ChulalongkornUniversity and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Sakun SantisukwongchoteDepartment of Pathology, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn, Memorial Hospital, 1873 Rama IV Road, Pathumwan, Bangkok, Thailand.
Piyada SitthideatphaiboonDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, ChulalongkornUniversity and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Nophol LeelayuwatanakulDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Krittiya KorphaisarnDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Poonchavist ChantranuwatDepartment of Pathology, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn, Memorial Hospital, 1873 Rama IV Road, Pathumwan, Bangkok, Thailand.
Virote SriuranpongDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, ChulalongkornUniversity and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Chatchawit AporntewanDepartment of Mathematics and Computer Sciences & Omics Sciences and Bioinformatics Center, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Nattiya HirankarnCenter of Excellence in Immunology and Immune-mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Chanida VinayanuwattikunDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, ChulalongkornUniversity and The King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Chanida.vi@chula.ac.th.

Funding

Health Systems Research Institute (Thailand) 66-153
6 · The paper itself

Abstract

The paradoxical impact of T-cell-derived circulating DNA (T-cirDNA) and prognostication in advanced non-small cell lung cancer (NSCLC) has been reported. Further exploration was conducted in 158 EGFR-mutated NSCLC participants who received EGFR inhibitors, correlated with tumor PD-L1 score, CD8 tumor-infiltrating lymphocytes (TILs), and bulk RNA sequencing. We categorized T-cirDNA levels into three groups based on a previous study: undetectable (26.8%), low (≤ 1% ratio; 36.6%), and high (> 1% ratio; 36.6%). Undetectable and high T-cirDNA groups were independent factors correlated with favorable outcomes. The presence of intra-tumoral CD8 TILs (≥ 1%) was also an independent unfavorable prognostic factor; however, it had the lowest proportion in the low T-cirDNA group (16%). Tumor-immune microenvironment (TIME)-related gene set enrichment analysis revealed an overlapped significant heme biosynthesis signature correlated with poor outcome and diverse T-cirDNA group. Despite a high heme biosynthesis signature score in the undetectable T-cirDNA group, inverse correlation with CIBERSORT-activated CD4 memory T-cells was found (R - 0.79, p-value 0.019). Those findings were contrary to the low and high T-cirDNA groups. The significant contribution of heme biosynthesis was the overexpression of CPOX. Crosstalk of EGFR and COPX function prohibits the activation of CD4 + memory T-cells or the spatial intra-tumoral CD8 + T-cells. Undetectable T-cirDNA represents inactivated naïve T-cells and solely active downstream EGFR signaling.

Indexed as

Carcinoma, Non-Small-Cell LungCell-Free Nucleic AcidsHemeLung NeoplasmsMutationT-LymphocytesTumor MicroenvironmentAgedCD8-Positive T-LymphocytesErbB ReceptorsFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisCell-Free Nucleic AcidsEGFR protein, humanErbB ReceptorsHemeEGFR tyrosine kinase inhibitorNon-small cell lung cancerT-cell-derived circulating DNATumor microenvironment

Identifiers

PMID41107392
PMCPMC12534490

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.